Skip to main content
Springer Nature Link
Log in

Complications of Cholestasis

  • Chapter
Cholestatic Liver Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1034 Accesses

Abstract

It is important to recognize the complications of cholestasis in patients with chronic cholestatic liver disease because of their prevalence and their pre- and post-transplant implications. Understanding and treating these conditions can result in a significant impact on morbidity and quality of life in this group of patients. Most of what is known is based on small studies of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), which is then extrapolated to patients with other cholestatic diseases. This section will review the pathophysiology and management of osteoporosis, pruritus, dyslipidemia, and vitamin deficiencies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, and Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transplant 2004; 10(5): 648–653.

    Article  Google Scholar 

  2. Menon KV, Angulo P, Weston S, Dickson ER, and Lindor KD. Bone disease in PBC: independent indicators and rate of progression. J Hepatol 2001; 35(3): 316–323.

    Article  CAS  PubMed  Google Scholar 

  3. Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RA, and LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14(2): 257–261.

    Article  CAS  PubMed  Google Scholar 

  4. Guichelaar MM, Malinchoc M, Sibonga JD, Clarke BL, and Hay JE. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res 2003; 18(12): 2190–2199.

    Article  PubMed  Google Scholar 

  5. Argao EA, Specker BL, and Heubi JE. Bone mineral content in infants and children with chronic cholestatic liver disease. Pediatrics 1993; 91(6): 1151–1154.

    CAS  PubMed  Google Scholar 

  6. Xu H and Eichstaedt H. Assessment of serial changes of bone mineral density at lumbar spine and femoral neck before and after liver transplantation. Chin Med J (Engl.) 1999; 112(4): 379–381.

    CAS  Google Scholar 

  7. Hay JE and Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9(4): 747–766.

    Article  PubMed  Google Scholar 

  8. Guanabens N, Pares A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in PBC. J Hepatol 2005; 42(4): 573–577.

    Article  CAS  PubMed  Google Scholar 

  9. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, and Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002; 36(4 Pt 1): 895–903.

    PubMed  Google Scholar 

  10. Skinner RK, Sherlock S, Long RG, and Wilis MR. 25-Hydroxylation of vitamin D in PBC. Lancet 1977; 1(8014): 720–721.

    Article  CAS  PubMed  Google Scholar 

  11. Kaplan MM, Goldberg MJ, Matloff DS, Neer RM, and Goodman DB. Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in PBC. Gastroenterology 1981; 81(4): 681–685.

    CAS  PubMed  Google Scholar 

  12. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, and Wolfe HJ. Osteoporosis in PBC: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83(1 Pt 1): 97–102.

    CAS  PubMed  Google Scholar 

  13. Herlong HF, Recker RR, and Maddrey WC. Bone disease in PBC: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83(1 Pt 1): 103–108.

    CAS  PubMed  Google Scholar 

  14. Crippin JS, Jorgensen RA, Dickson ER, and Lindor KD. Hepatic osteodystrophy in PBC: effects of medical treatment. Am J Gastroenterol 1994; 89(1): 47–50.

    CAS  PubMed  Google Scholar 

  15. Pares A, Guanabens N, and Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in PBC. Eur J Gastroenterol Hepatol 2005; 17(3): 311–315.

    Article  CAS  PubMed  Google Scholar 

  16. Lakatos LP, Bajnok E, Hegedus D, Toth T, Lakatos P, and Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with PBC. Eur J Gastroenterol Hepatol 2002; 14(7): 733–740.

    Article  CAS  PubMed  Google Scholar 

  17. Koshihara Y, Hoshi K, Ishibashi H, and Shiraki M. Vitamin K2 promotes 1alpha, 25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif. Tissue Int 1996; 59(6): 466–473.

    CAS  PubMed  Google Scholar 

  18. Kameda T, Miyazawa K, Mori Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis Biochem Biophys. Res Commun 1996; 220(3): 515–519.

    CAS  Google Scholar 

  19. Iwamoto J, Takeda T, and Sato Y. Effects of vitamin K2 on osteoporosis. Curr Pharm Des 2004; 10(21): 2557–2576.

    Article  CAS  PubMed  Google Scholar 

  20. Shiomi S, Nishiguchi S, Kubo S, et al. Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 2002; 97(4): 978–981.

    Article  CAS  PubMed  Google Scholar 

  21. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, and Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95(6): 2581–2586.

    Article  CAS  PubMed  Google Scholar 

  22. Olsson R, Mattsson LA, Obrant K, and Mellstrom D. Estrogen—progestogen therapy for low bone mineral density in PBC. Liver 1999; 19(3): 188–192.

    Article  CAS  PubMed  Google Scholar 

  23. Menon KV, Angulo P, Boe GM, and Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in PBC. Am J Gastroenterol 2003; 98(4): 889–892.

    Article  CAS  PubMed  Google Scholar 

  24. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637–645.

    Article  CAS  PubMed  Google Scholar 

  25. Levy C, Harnois DM, Angulo P, Jorgensen R, and Lindor KD. Raloxifene improves bone mass in osteopenic women with PBC: results of a pilot study. Liver Int 2005; 25(1): 117–121.

    Article  CAS  PubMed  Google Scholar 

  26. Guanabens N, Pares A, del Rio L, et al. Sodium fluoride prevents bone loss in PBC. J Hepatol 1992; 15(3): 345–349.

    Article  CAS  PubMed  Google Scholar 

  27. Guanabens N, Pares A, Monegal A, et al. Etidronate versus fluoride for treatment of osteopenia in PBC: preliminary results after 2 years. Gastroenterology 1997; 113(1): 219–224.

    Article  CAS  PubMed  Google Scholar 

  28. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, and Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33(6): 878–882.

    Article  CAS  PubMed  Google Scholar 

  29. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with PBC. Am J Gastroenterol 2003; 98(10): 2268–2274.

    CAS  PubMed  Google Scholar 

  30. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; (4): 1 762–771.

    Article  CAS  Google Scholar 

  31. Camisasca M, Crosignani A, Battezzati PM, et al. Parenteral calcitonin for metabolic bone disease associated with PBC. Hepatology 1994; 20(3): 633–637.

    Article  CAS  PubMed  Google Scholar 

  32. Hay JE, Malinchoc M, and Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with PBC and primary sclerosing cholangitis. J Hepatol 2001; 34(2): 292–298.

    Article  CAS  PubMed  Google Scholar 

  33. Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005; 187(3): 311–325.

    Article  CAS  PubMed  Google Scholar 

  34. Adams J and Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm 2005; 62(15): 1574–1581.

    Article  CAS  PubMed  Google Scholar 

  35. Nishiguchi S, Shimoi S, Kurooka H, et al. Randomized pilot trial of vitamin K2 for bone loss in patients with PBC. J Hepatol 2001; 35(4): 543–545.

    Article  CAS  PubMed  Google Scholar 

  36. Mela M, Mancuso A, and Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003; 17(7): 857–870.

    Article  CAS  PubMed  Google Scholar 

  37. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109(5): 678–681.

    Article  CAS  PubMed  Google Scholar 

  38. O’Keeffe C, Baird AW, Nolan N, and McCormick PA. Cholestatic pruritus—the role of cutaneous mast cells and nerves. Aliment Pharmacol Ther 2004; 19(12): 1293–1300.

    Article  PubMed  Google Scholar 

  39. Jones EA and Zylicz Z. Treatment of pruritus caused by cholestasis with opioid antagonists. J Palliat Med 2005; 8(6): 1290–1294.

    Article  CAS  PubMed  Google Scholar 

  40. Koenigstein H. Experimental study of itch stimuli in animals. Arch Dermatol Syph 1948; 57: 828–849.

    CAS  Google Scholar 

  41. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, and Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103(2): 630–635.

    CAS  PubMed  Google Scholar 

  42. Nelson L, Vergnolle N, D’Mello C, Chapman K, Le T, and Swain MG. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 2005; 27: 1–9.

    Google Scholar 

  43. Kuraishi Y, Yamaguchi T, and Miyamoto T. Itch-scratch responses induced by opioids through central mu opioid receptors in mice. J Biomed Sci 2000; 7(3): 248–252.

    Article  CAS  PubMed  Google Scholar 

  44. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, and Jones EA. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1991; 15(1–2): 220–224.

    Google Scholar 

  45. Datta DV and Sherlock S. Cholestyramine for long term relief of the pruritus complicating Intrahepatic cholestasis. Gastroenterology 1966; 50(3): 323–332.

    CAS  PubMed  Google Scholar 

  46. Price TJ, Patterson WK, and Olver IN. Rifampicin as treatment for pruritus in malignant cholestasis. Support Care Cancer 1998; 6(6): 533–535.

    Article  CAS  PubMed  Google Scholar 

  47. Bachs L, Pares A, Elena M, Piera C, and Rodes J. Effects of long-term rifampicin administration in PBC. Gastroenterology 1992; 102(6): 2077–2080.

    CAS  PubMed  Google Scholar 

  48. Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of PBC with rifampin. Dig Dis Sci 1991; 36(2): 216–220.

    Article  CAS  PubMed  Google Scholar 

  49. Miguet JP, Mavier P, Soussy CJ, and Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology 1977; 72(5 Pt 1): 924–926.

    CAS  PubMed  Google Scholar 

  50. Galeazzi R, Lorenzini I, and Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980; 25(2): 108–112.

    Article  CAS  PubMed  Google Scholar 

  51. Bachs L, Pares A, Elena M, Piera C, and Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1(8638): 574–576.

    Article  CAS  PubMed  Google Scholar 

  52. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, and Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999; 29(4): 442–447.

    Article  CAS  PubMed  Google Scholar 

  53. Prince MI, Burt AD, and Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50(3): 436–439.

    Article  CAS  PubMed  Google Scholar 

  54. Bergasa NV, Alling DW, Talbot TL, Wells MC, and Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41(3 Pt 1): 431–134.

    Article  CAS  PubMed  Google Scholar 

  55. Thornton JR and Losowsky MS. Opioid peptides and PBC. BMJ 1988; 297(6662): 1501–1504.

    Article  CAS  PubMed  Google Scholar 

  56. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123(3): 161–167.

    CAS  PubMed  Google Scholar 

  57. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, and Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113(4): 1264–1269.

    Article  CAS  PubMed  Google Scholar 

  58. McRae CA, Prince MI, Hudson M, Day CP, James O, and Jones D. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003; 125(2): 591–596.

    Article  PubMed  Google Scholar 

  59. Browning J, Combes B, and Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with PBC. Am J Gastroenterol 2003; 98(12): 2736–2741.

    Article  CAS  PubMed  Google Scholar 

  60. Mayo M, Handem I, Saldana S, Jacobe H, Getachew Y, and Rush AJ. Effect of sertraline on pruritus in cholestatic liver disease: a randomized double blind placebo controlled crossover study. Hepatology 2005; 42(4 Suppl 1): 209A.

    Google Scholar 

  61. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10(10): 865–870.

    Article  CAS  PubMed  Google Scholar 

  62. O’Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, and Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005; 21(8): 1041–1045.

    Article  PubMed  CAS  Google Scholar 

  63. Horsmans Y and Geubel AP. Pruritus associated with cholestatic liver disease. Ann Intern Med 1996; 125(8): 701.

    CAS  PubMed  Google Scholar 

  64. Cadranel JF, Di Martino V, and Devergie B. Grapefruit juice for the pruritus of cholestatic liver disease. Ann Intern Med 1997; 126(11): 920–921.

    CAS  PubMed  Google Scholar 

  65. Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Burgstaler EA, and Carlson GL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet 1980; 2(8185): 53–55.

    Article  CAS  PubMed  Google Scholar 

  66. Stange J, Hassanein TI, Mehta R, Mitzner SR, and Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif. Organs 2002; 26(2): 103–110.

    Article  PubMed  Google Scholar 

  67. Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, et al. Therapy of intractable pruritus with MARS. Transplant Proc 2005; 37(3): 1480–1481.

    Article  CAS  PubMed  Google Scholar 

  68. Bellmann R, Graziadei IW, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transplant 2004; 10(1): 107–114.

    Article  Google Scholar 

  69. Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with PBC. Am J Gastroenterol 2004; 99(6): 1105–1110.

    Article  PubMed  Google Scholar 

  70. Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97(8): 2117–2119.

    Article  PubMed  Google Scholar 

  71. Gluud C and Christensen E. Ursodeoxycholic acid for PBC. Cochrane Database Syst Rev 2002; (1): CD000551.

    Google Scholar 

  72. Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in PBC. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89(6): 1266–1278.

    CAS  PubMed  Google Scholar 

  73. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in PBC. Gut 2002; 51(2): 265–269.

    Article  CAS  PubMed  Google Scholar 

  74. Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in PBC: what is the risk? Hepatology 1992; 15(5): 858–862.

    Article  CAS  PubMed  Google Scholar 

  75. Agorastos J, Fox C, Harry DS, and McIntyre N. Lecithin—cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice. Clin Sci Mol Med 1978; 54(4): 369–379.

    CAS  PubMed  Google Scholar 

  76. Edwards CM, Otal MP, and Stacpoole PW. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells. Metabolism 1993; 42(7): 807–813.

    Article  CAS  PubMed  Google Scholar 

  77. Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, and Ramadori G. Simvastatin in PBC: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36(4): 454–458.

    Article  CAS  PubMed  Google Scholar 

  78. Kurihara T, Akimoto M, Abe K, et al. Experimental use of pravastatin in patients with PBC associated with hypercholesterolemia. Clin Ther 1993; 15(5): 890–898.

    CAS  PubMed  Google Scholar 

  79. Phillips JR, Angulo P, Petterson T, and Lindor KD. Fat-soluble vitamin levels in patients with PBC. Am J Gastroenterol 2001; 96(9): 2745–2750.

    Article  CAS  PubMed  Google Scholar 

  80. Arria AM, Tarter RE, Warty V, and Van Thiel DH. Vitamin E deficiency and psychomotor dysfunction in adults with PBC. Am J Clin Nutr 1990; 52(2): 383–390.

    CAS  PubMed  Google Scholar 

  81. Jeffrey GP, Muller DP, Burroughs AK, et al. Vitamin E deficiency and its clinical significance in adults with PBC and other forms of chronic liver disease. J Hepatol 1987; 4(3): 307–317.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern, Dallas, TX

    Abhitabh Patil MD & Marlyn J. Mayo MD

Authors
  1. Abhitabh Patil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marlyn J. Mayo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic, Rochester, MN

    Keith D. Lindor MD  & Jayant A. Talwalkar MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Patil, A., Mayo, M.J. (2008). Complications of Cholestasis. In: Lindor, K.D., Talwalkar, J.A. (eds) Cholestatic Liver Disease. Clinical Gastroenterology. Humana Press. https://doi.org/10.1007/978-1-59745-118-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-118-5_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-838-6

  • Online ISBN: 978-1-59745-118-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics